Please assess the completion status of the following clinical trial:

Trial Title: Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed squamous cell lung cancer~* Newly diagnosed untreated Stage IV and/or recurrent after adjuvant therapy with metastatic disease~* Patients previously treated with immune checkpoint inhibitor therapy are eligible~* Measurable disease as per RECIST 1.1~* Greater than 6 months since receiving neo-adjuvant or adjuvant chemotherapy.~* Age ≥ 18 years~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1~* Women of childbearing potential and sexually active men enrolled in the study must agree to practice effective contraception method during treatment and for three months after completing treatment~* Negative serum or urine β-hCG pregnancy test at screening for patients of childbearing potential~* \< Grade 2 pre-existing peripheral neuropathy (per CTCAE)~* Marrow and organ function as follows:~* ANC ≥ 1500 cells/mm3~* Platelets \> 100,000 cells/mm3~* Hemoglobin\>9g/dL~* Creatinine clearance ≥ 40mL/min~* Bilirubin ≤ 1.5 mg/dL~* AST/ALT≤2.5 x upper limit of normal range (ULN),~* alkaline phosphatase ≤ 2.5 X upper limit of normal, unless bone metastasis in present in the absence of liver metastasis~Exclusion Criteria:~* Prior treatment with albumin-bound paclitaxel or gemcitabine~* Prior systemic anticancer therapy for advanced squamous cell lung cancer~* Untreated brain metastasis. Patients with treated brain metastases who are off steroids are eligible~* Peripheral neuropathy greater than grade 1~* Malignancies within the past 5 years other than non-melanoma skin cancer or insitu cervical cancer status post treatment~* Patients with other serious medical illnesses including, ongoing or active infection, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements~* Class III or IV congestive heart failure by New York Heart Association

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Albumin-Bound Paclitaxel and Gemcitabine (Type: EXPERIMENTAL): During each 21-day cycle, albumin-bound paclitaxel at 100mg/mg2 over 120 minutes and gemcitabine at 1000mg/m2 over 30 minutes will be given intravenously on days 1 and 8 of each 21 day cycle. Treatment will continue until disease progression or intolerable side effects. After the 4th cycle of treatment, patients will have the option of discontinuing gemcitabine and proceeding with weekly albumin-bound paclitaxel as maintenance therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).